An 83-amino-acid modified version of insulin-like growth factor-1 (IGF-1) with an arginine substitution at position 3 and a 13-amino-acid N-terminal extension. These modifications reduce binding to IGF binding proteins (IGFBPs), resulting in a much longer effective half-life and greater bioavailability than native IGF-1.
IGF-1 LR3 (Long Arg3 Insulin-like Growth Factor-1) is an 83-amino-acid synthetic analog of human IGF-1 (70 amino acids). Two modifications distinguish it from native IGF-1: (1) an arginine replacing glutamic acid at position 3 (Arg3), and (2) a 13-amino-acid N-terminal extension peptide.
These modifications dramatically reduce IGF-1 LR3's binding to the 6 IGF binding proteins (IGFBPs) that normally sequester and inactivate circulating IGF-1. With reduced IGFBP binding, more IGF-1 LR3 remains free and bioactive, extending its effective half-life from ~15 minutes (native IGF-1) to approximately 20-30 hours.
IGF-1 LR3 (Insulin-like Growth Factor 1, Long Arg3) is an 83-amino-acid analog of human IGF-1 that has been modified to have dramatically reduced binding to IGF-binding proteins (IGFBPs). In normal physiology, over 95% of circulating IGF-1 is bound to IGFBPs (particularly IGFBP-3), which regulate its bioavailability and half-life. IGF-1 LR3's reduced IGFBP binding means a much larger fraction remains in its free, biologically active form — resulting in significantly more potent anabolic and mitogenic effects compared to native IGF-1.
The modifications that create LR3 are: substitution of arginine for glutamic acid at position 3 (reducing IGFBP affinity), and an N-terminal extension of 13 amino acids. Together, these changes extend the effective half-life from ~12-15 hours (native IGF-1) to approximately 20-30 hours and increase potency roughly 2-3 fold.
IGF-1 LR3 is primarily used in research and by bodybuilders/athletes seeking enhanced muscle growth and recovery. It is not FDA-approved and has limited human clinical data. Its potent anabolic effects carry significant risks, particularly regarding insulin sensitivity and potential tumor promotion, that differentiate it from milder GH secretagogues like ipamorelin or sermorelin.
IGF-1 LR3 is the most potent commercially available form of IGF-1. By escaping IGFBP sequestration, it maintains high free IGF-1 levels for 20-30 hours, continuously activating IGF-1R on muscle cells (promoting hypertrophy), fat cells (promoting lipolysis), and satellite cells (promoting regeneration). The mTOR activation is particularly important for muscle protein synthesis — it's the same pathway that leucine and resistance training activate, but IGF-1 LR3 provides sustained stimulation.
| Pathway | Effect | Significance |
|---|---|---|
| Reduced IGFBP binding | Arg3 substitution + N-terminal extension prevent IGFBP sequestration | 3x greater bioactivity than native IGF-1 |
| PI3K-Akt-mTOR | Activates the master anabolic signaling cascade | Increases muscle protein synthesis and inhibits protein degradation |
| Ras-MAPK | Promotes cell proliferation and differentiation | Satellite cell activation for muscle regeneration |
| Anti-apoptotic | Akt phosphorylates Bad, blocking the apoptotic cascade | Promotes cell survival under stress |
| Lipolysis | IGF-1R signaling in adipocytes promotes fat breakdown | Reduces body fat while preserving/building lean mass |
| Study | Design | Findings | Level |
|---|---|---|---|
| Muscle hypertrophy | Preclinical + in vitro | IGF-1 LR3 is ~3x more potent than native IGF-1 in stimulating muscle cell proliferation and differentiation | Preclinical |
| Bioavailability | Pharmacokinetic studies | 20-30 hour effective half-life vs 15 minutes for native IGF-1. Reduced IGFBP binding confirmed. | Level II |
| Wound healing | Preclinical | Accelerated wound closure and tissue remodeling in animal models | Preclinical |
| Mecasermin (native IGF-1) | FDA-approved analog (Increlex) | Native recombinant IGF-1 (not LR3) is FDA-approved for severe IGF-1 deficiency. Provides clinical validation of IGF-1R pathway. | Level I (for native IGF-1) |
Hypoglycemia: IGF-1 LR3 can cause significant hypoglycemia by activating insulin receptors (IGF-1 and insulin receptors share structural homology). This is a serious and potentially dangerous side effect, particularly at higher doses or when combined with insulin. Blood glucose monitoring is essential.
Tumor promotion: IGF-1 is a potent mitogenic (growth-promoting) signal. Elevated IGF-1 levels are epidemiologically associated with increased risk of certain cancers (colorectal, breast, prostate). IGF-1 LR3's enhanced potency and bioavailability amplify this concern. Use is strongly contraindicated in individuals with any history of cancer.
Organ growth: Unlike GH secretagogues (which produce modest, physiological increases in GH/IGF-1), exogenous IGF-1 LR3 can produce supraphysiological IGF-1 levels that may promote unwanted organ growth (visceral organ enlargement) with chronic use.
Insulin resistance: Chronic supraphysiological IGF-1 levels can paradoxically impair insulin sensitivity, worsening metabolic health over time.
No human clinical trials: IGF-1 LR3 has no formal human safety studies. All safety information is extrapolated from native IGF-1 data and anecdotal user reports.
| Jurisdiction | Status |
|---|---|
| FDA | NOT approved. Native IGF-1 (mecasermin/Increlex) is approved for severe primary IGF-1 deficiency. |
| WADA | Banned under S2 (peptide hormones and growth factors) |
| Availability | Available as a research chemical. Commonly used in bodybuilding communities. |